Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

cessful NDA filing and furthering our discussions with potential collaboration partners."

Based upon the discussions with FDA, Palatin intends to finalize the protocols for the pivotal Phase 3 clinical studies and start screening patients later this year.

Quarter Ended March 31, 2013 Financial Results
For the three months ended March 31, 2013, Palatin reported a net loss of $4.0 million, or $(0.04) per basic and diluted share, compared to a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the same period in 2012. 

The decrease in net loss for the quarter ended March 31, 2013, compared to the same period last fiscal year, is attributable to a decrease in operating expenses primarily related to Palatin's Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. 

Revenue
Palatin did not recognize any revenues for the quarter ended March 31, 2013, compared to $23,996 for the quarter ended March 31, 2012.  Revenue consists of contract revenue under our collaboration agreement with AstraZeneca.

Costs and Expenses
Total operating expenses for the quarter ended March 31, 2013 were $4.0 million compared to $6.1 million for the comparable quarter of 2012.  The decrease in operating expenses for the quarter was primarily due to Palatin's Phase 2B clinical trial with bremelanotide for FSD and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of the laboratory facilities in July 2012.

Cash Position
As of March 31, 2013, Palatin had cash and cash equivalents of $23.5 million, $6.0 million in short term investments and current liabilities of $2.7 million.  Cash and cash equivalents as of June 30, 2012 were $3.8 million with current liabilities of $3.5 million. 

Palatin believes that its existing capital resources will be adequate to fund its currently planned opera
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... That is, most of the atoms in our ... in the outer parts of atoms equals the number ... one or more electrons are plucked away from the ... pull from the nucleus. This enhanced pull, causing ... electrons are less vulnerable to the distractions of their ...
(Date:7/18/2014)... , July 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... of Directors appointed Co-Chairmen Charles S. Ramat ... on an interim basis, effective immediately. Messrs. Ramat and ... no longer Chief Executive Officer of Neurotrope Bioscience, Inc., ... and whose employment agreement with Neurotrope Bioscience Inc. terminated ...
(Date:7/18/2014)... Emerging Nuclear Power Countries - Market Forecast, ... , The latest report from GlobalData, Emerging Nuclear Power ... to 2030 covers the emerging nuclear market and the ... on key market players and their global market share. ... across the world has also been estimated. , To ...
Breaking Biology Technology:Highly charged ions 2Highly charged ions 3Highly charged ions 4Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 2Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 3Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs 4Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... electrical hair that lets them link up in ... Southern California biophysicist and his collaborators. The ... and share energy in part through electrically conducting ... the first measurement of electron transport along biological ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... product candidate, fidaxomicin, will be presented ... Disease Society of America (IDSA) to be held at ... on October 21-24, 2010. (Logo: ...
... N.J. Physicists at Rutgers University have discovered new ... and inexpensive plastic solar cells for pollution-free electricity production. ... in an upcoming issue of the journal Nature ... of light can travel on the order of a ...
Cached Biology Technology:Microbial hair: It's electric 2Microbial hair: It's electric 3Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2
(Date:7/21/2014)... has issued a high health risk warning for Yellowknife ... region due to forest fires. Currently 160 wildfires ... plans for evacuation since these fires are endangering people ... area recently comes with mixed results. The rains ... to start others. , This year the Northern Territories ...
(Date:7/21/2014)... School of Medicine-led study suggests that parents of obese ... consequences of childhood weight gain or the importance of ... healthy weight. , The study is published online in ... Dietetics . , "Parents have a hard time changing ... author Kyung Rhee, MD, and an assistant adjunct professor ...
(Date:7/21/2014)... Aqua satellites detected 154 hotspots in areas across Riau ... fires had increased again following a decline in rainfall. ... was far higher than what had been reported one ... The hotspots were scattered in six regencies and municipalities, ... Smoke and the related haze it creates could potentially ...
Breaking Biology News(10 mins):Parents rank their obese children as 'very healthy' 2
... A newly identified defect in a DNA repair system might ... a key chemotherapy drug, possibly putting them at greater risk ... by St. Jude Children,s Research Hospital scientists. The ... acute lymphoblastic leukemia (ALL) patients who are at higher risk ...
... compound tested by UT Southwestern Medical Center investigators destroys several ... 30 million people in the worldwide pandemic of 1918. ... of a human antiviral protein - could potentially be developed ... that tends to mutate into strains resistant to anti-influenza drugs. ...
... [Brown University] Take your time. Hold your horses. ... arguably equal choices, they need time to deliberate. In ... for Parkinson,s disease, that process sometimes doesn,t kick in, ... happens has led scientists to a detailed explanation of ...
Cached Biology News:Newly identified DNA repair defect linked to increased risk of leukemia relapse 2Newly identified DNA repair defect linked to increased risk of leukemia relapse 3Compound kills highly contagious flu strain by activating antiviral protein 2DBS studies show how brain buys time for tough choices 2DBS studies show how brain buys time for tough choices 3
UGT1A7 (E-15)...
... peptide corresponding to the third cytoplasmic loop ... conjugated to KLH. The immunizing peptide has ... gene. Physical form: Solution in phosphate ... azide. Titertest method: IHC (p). ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
... easy to use Ascent Software ... members of the Ascent microplate ... clear and easy-to-follow approach with ... and highly sophisticated data handling, ...
Biology Products: